Mutations in the sodium channel gene SCN2A cause neonatal epilepsy with late-onset episodic ataxia

Schwarz, N.

2016-02


http://hdl.handle.net/10138/173743
https://doi.org/10.1007/s00415-015-7984-0

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail.
Please cite the original version.
Mutations in the sodium channel gene SCN2A cause neonatal epilepsy with late-onset episodic ataxia

N. Schwarz, MD¹, A. Hahn, MD², T. Bast, MD¹, S. Müller, Dipl. Biol.¹, H. Löffler¹, S. Maljevic, PhD¹, E. Gaily, MD, PhD⁴, I. Prehl, Dipl. Biol.⁵, S. Biskup, MD, PhD⁵,⁶, T. Joensuu, PhD⁷, A.-E. Lehesjoki, MD, PhD⁷, B. A. Neubauer, MD², H. Lerche, MD¹, U.B.S. Hedrich, PhD¹

¹Dept. of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; ² Department of Neuropediatrics, University Medical Clinic Giessen, Germany; ³ Epilepsy Center Kork, Kehl-Kork, Germany; ⁴ Department of Pediatric Neurology, Children’s Hospital, Helsinki University Hospital, Helsinki, Finland; ⁵ CeGaT GmbH; Dept. of Neurology with focus on Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; ⁶ Hertie Institute for Clinical Brain Research, University of Tübingen, and German Center for Neurodegenerative Diseases (DZNE) Tübingen, Germany; ⁷ Folkhälsan Institute of Genetics, Neuroscience Center and Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland

Corresponding author: Prof. Dr. Holger Lerche
Corresponding author’s address: Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Str. 3 72076 Tübingen, Germany
Corresponding author’s phone and fax: Tel.: +49-7071-29-80466, Fax: +49-7071-29-4488
Corresponding author’s e-mail address: holger.lerche@uni-tuebingen.de

Acknowledgements

The authors thank all patients and their parents for participating in this study. We thank Markus Lommi, Ann-Liz Träskelin and Paula Hakala for technical assistance, Dr. Julian Schubert and Stefanie Garkisch for their help with analysis of genetic data. This work was supported by the German Research Foundation (DFG Le1030/10-2, Le1030/11-1 to HL, 416/5-1 to BAN) and the Folkhälsan Research Foundation (A-EL), partly in the frame of the EuroEPINOMICS programme of the European Science foundation.
Abstract

Mutations in \textit{SCN2A} cause epilepsy syndromes of variable severity including neonatal-infantile seizures. In one case, we previously described additional childhood-onset episodic ataxia. Here, we corroborate and detail the latter phenotype in three further cases. We describe the clinical characteristics, identify the causative \textit{SCN2A} mutations and determine their functional consequences using whole-cell patch-clamping in mammalian cells. In total, four probands presented with neonatal-onset seizures remitting after five to 13 months. In early childhood, they started to experience repeated episodes of ataxia, accompanied in part by headache or backpain lasting minutes to several hours. In two of the new cases, we detected the novel mutation p.Arg1882Gly. While this mutation occurred \textit{de novo} in both patients, one of them carries an additional known variant on the same \textit{SCN2A} allele, inherited from the unaffected father (p.Gly1522Ala). Whereas p.Arg1882Gly alone shifted the activation curve by -4 mV, the combination of both variants did not affect activation, but caused a depolarizing shift of voltage-dependent inactivation, and a significant increase in Na$^+$ current density and protein production. p.Gly1522Ala alone did not change channel gating. The third new proband carries the same \textit{de novo} \textit{SCN2A} gain-of-function mutation as our first published case (p.Ala263Val). Our findings broaden the clinical spectrum observed with \textit{SCN2A} gain-of-function mutations, showing that fairly different biophysical mechanisms can cause a convergent clinical phenotype of neonatal seizures and later onset episodic ataxia.

\textbf{Key words:} Epilepsy, genetics, ataxia, channelopathy, sodium channel
Introduction

Gene discovery in epilepsy and related neurological syndromes, such as migraine, paroxysmal dyskinesia and episodic ataxia, has revealed that mutations in ion channels, transporters, or synaptic proteins play a crucial role in their pathophysiology [1-3]. These mutations affect the excitability of different neuronal subtypes and compartments. The altered excitability, sometimes provoked by typical decompensating triggers, episodically induces a dysfunction of neuronal networks in distinct brain regions thereby causing well-defined paroxysmal clinical symptoms. Beside ‘pure’ syndromes with only one characteristic clinical feature, several overlap syndromes with epilepsy as a core phenotype have been described [4,5].

The neuronal voltage-gated Na\(^+\) channel Nav1.2, encoded by the SCN2A gene, is mutated in benign familial neonatal-infantile seizures (BFNIS), an autosomal dominant epilepsy syndrome characterized by transient seizures in the first weeks or months of life [6,7]. These mutations mainly lead to gain-of-function defects causing neuronal hyperexcitability [8,7]. More severe, non-familial phenotypes with neonatal onset seizures caused by de novo SCN2A mutations are increasingly described [9-14]. One loss-of-function mutation causes epileptic encephalopathy with later onset [15].

We previously described a single patient with neonatal-onset, relatively severe epilepsy resolving at 13 months of age, with episodes of ataxia, myoclonus and pain starting at 18 months of age. We identified a de novo missense mutation in SCN2A showing a gain-of-function defect [3]. Here, we describe three further independent cases with neonatal-onset seizures and episodic ataxia starting in early childhood. We reveal the common clinical features, the underlying SCN2A mutations and their pathophysiological mechanisms.
Materials and methods

Patients

Clinical evaluation of the first new case (patient #1) and follow-up of the previously described one (#4) were performed in Helsinki. The other two new patients were examined at the University Clinic Giessen (patient #2) or at the Epilepsy Center Kork (patient #3). All patients were selected from routine clinical presentations in the respective centers and underwent subsequent genetic testing due to clinical suspicion of an SCN2A defect, since they presented highly similarly as case #4.

Molecular Genetics

Patient #1 underwent direct (Sanger) sequencing of SCN2A. For patients #2 and #3 an epilepsy gene panel screening was performed as reported previously [16]. Confirmation of the mutations and segregation was performed by Sanger sequencing. Long range PCR was used to determine if the two variants detected in patient #2 were on the same allele.

For SCN2A sequencing genomic DNA was isolated from EDTA-blood. The coding exons and exon-intron boundaries of SCN2A in patients #2 and #3, and mutation-carrying exons in their parents, were amplified (primers available upon request). SCN2A in patient #4 and her parents was amplified (primers available upon request) by the Qiagen Multiplex PCR kit, and by the Expand Long Range PCR kit (Cat. No. 04829034001 Roche, Mannheim, Germany) on a Biometra T3 thermocycler (Biometra, Göttingen, Germany). Long range PCR products were cloned (TOPO® XL PCR Cloning Kit, Cat. No. K4700-10) and finally sequenced. For long range PCR, covering both detected variants chromosomal position 166242926-66246608 (forward: ATCGTGCCACTGACTCCAACC, reverse: CTATCGTCTGATGAGTCCATTACGCC) was amplified resulting in a 3682 bp fragment. Sequencing reactions were performed using ABI PRISM® BigDye® Terminator v3.1Cycle Sequencing Kit (Applied Biosystems, Weiterstadt, Germany). Capillary electrophoresis was conducted on an ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems, Weiterstadt, Germany) or an ABI 3730 DNA Analyzer (Perkin Elmer, Foster City, CA, U.S.A.).

Mutagenesis

To engineer the mutations into the adult splice variant of the human Na\textsubscript{v}1.2 channel, site-directed mutagenesis was performed using Quickchange® II XL (Agilent Technologies, Santa Clara, CA, USA; primers are available upon request) for the R1882G mutation and GoTaq® Long PCR Master Mix (Promega Corporation, Madison, WI, USA; primers are available upon request) for the G1522A and G1522A + R1882G mutations. Before used in experiments, the mutant cDNA was fully resequenced to verify the introduced mutations and exclude any additional sequence alterations. GlaxoSmithKline (Brentford, UK) kindly provided the human Na\textsuperscript{+} channel subunits hβ\textsubscript{1} and hβ\textsubscript{2} in the pCLH vector. The hygromycin coding region in the vector was exchanged with the sequence coding for either enhanced green fluorescent protein (EGFP) or CD8 marker genes to obtain pCLH-hβ1-EGFP and pCLH-hβ2-CD8 [3,17].
Transfection and expression in tsA201 cells

Human tsA201 cells were cultured at 37°C, with 5% CO₂ humidified atmosphere and grown in 89% Dulbecco’s modified Eagle medium (Invitrogen, Carlsbad, CA, USA) + 10% (v/v) foetal bovine serum (PAN-Biotech GmbH, Aidenbach, Germany) + 1% L-Glutamin 200 mM (Biochrom GmbH, Berlin, Deutschland). Transfections using Mirus TransIT®-LT1 reagent (Madison, WI 53711 USA) were performed for transient expression of wild-type or mutant Na⁺ channel α-subunits together with β₁- and β₂-subunits in tsA-201 cells. For co-expression of α- and both β-subunits 2.4 µg of total DNA (2.0 µg α-subunit, 0.2 µg β₁-subunit and 0.2 µg β₂-subunit) was transfected in a molar ratio of 1:1:1. Anti-CD8 antibody-coated microbeads (Dynabeads M450, Dynal, Norway) were suspended in phosphate buffered saline and added to the cells. Cells positive for both CD8 antigen and EGFP fluorescence were used for electrophysiological recordings.

Western Blot

For protein identification we applied 35 µg per line of total cell lysate on a 6% SDS gel. After separation and blotting, the Protran® Nitrocellulose Membranes was blocked with 5% skim milk powder/PBS/0.1% Tween 20 and incubated with mouse monoclonal anti-SCN2A antibody 1:500 (overnight, 4 °C) in 1% skim milk powder/PBS/0.1% Tween 20. As secondary antibody HRP conjugated goat anti-mouse serum 1:10,000 (1 h, RT) was used. Western Blots were developed using the Mini-PROTEAN® Tetra Cell according to the manufactures procedures. Quantification of signals was performed using ImageJ software (NIH, Bethesda, MD). Expression of NaV1.2 proteins were normalized to corresponding Vinculin signals in total lysates and pooled from different experiments.

Electrophysiology

Standard whole-cell patch clamp recordings were performed using an Axopatch 200B amplifier, a Digidata 1320A digitizer and pCLAMP 8 data acquisition software (Axon Instruments, Union City, CA, USA), as has been described before [7]. Leakage and capacitive currents were automatically subtracted using a pre-pulse protocol (-P/4). Currents were filtered at 5 kHz and digitized at 20 kHz. Cells were visualized using an inverted microscope (Axio-Vert.A1; Zeiss). All recordings were performed at room temperature of 21–23°C. Na⁺ currents of 1-12 nA were recorded from transfected tsA201 cells 10 min after establishing the whole cell configuration. Borosilicate glass pipettes had a final tip resistance of 1-2 MΩ when filled with internal recording solution (see below). We carefully checked that the maximal voltage error due to residual series resistance after up to 95% compensation was always <5 mV. The pipette solution contained (in mM): 5 NaCl, 2 MgCl₂, 5 EGTA, 10 (4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES), 130 CsF (pH 7.4, 290 mOsm). The bath solution contained (in mM) 140 NaCl, 4 KCl, 1 MgCl₂, 2 CaCl₂, 5 HEPES, 4 Dextrose (pH 7.4, 300 mOsm).
Voltage clamp protocols and data analysis: The activation curve (conductance–voltage relationship) was derived from the current–voltage relationship obtained by plotting the peak current over various step depolarizations (7.5 mV steps from a holding potential of -140 mV) according to

\[ g(V) = \frac{I}{(V - V_{rev})} \]

with \( g \) being the conductance, \( I \) the recorded peak current at test potential \( V \), and \( V_{rev} \) the apparent observed Na\(^+\) reversal potential.

The voltage-dependence of activation was fit with the following Boltzmann function:

\[ g(V) = \frac{g_{max}}{1 + \exp[(V - V_{1/2})/k_V]} \]

with \( g \) being the conductance, \( I \) the recorded current amplitude at test potential \( V \), \( V_{rev} \) the Na\(^+\) reversal potential, \( g_{max} \) the maximal conductance, \( V_{1/2} \) the voltage of half-maximal activation and \( k_V \) a slope factor. Steady-state inactivation was determined using 300 ms conditioning pulses to various potentials followed by the test pulse to -20 mV at which the peak current reflected the percentage of non-inactivated channels. A standard Boltzmann function was fit to the inactivation curves:

\[ I(V) = \frac{I_{max}}{1 + \exp[(V - V_{1/2})/k_V]} \]

with \( I \) being the recorded current amplitude at the conditioning potential \( V \), \( I_{max} \) being the maximal current amplitude, \( V_{1/2} \) the voltage of half-maximal inactivation and \( k_V \) a slope factor. For analysis of the time constants of fast inactivation, the cell membrane was depolarized to various test potentials from a holding potential of -140 mV to record Na\(^+\) currents. A second-order exponential function was best fit to the time course of fast inactivation during the first 70 ms after onset of the depolarization, yielding two time constants. The weight of the second slower time constant was relatively small. Only the fast time constant, named \( \tau_h \), was therefore used for data presentation in the ‘Results’ section. Persistent Na\(^+\) currents (\( I_{SS} \), for the ‘steady-state’ current) were determined at the end of depolarizing pulses, lasting 95 ms, to different test potentials and are given relative to the initial peak current (\( I_{PEAK} \)). Recovery from fast inactivation was recorded from holding potentials of -140 mV. Cells were depolarized to -20 mV for 100 ms to inactivate all Na\(^+\) channels and then repolarized to various recovery potentials (-80, -100 or -120 mV) for increasing duration. A second-order exponential
function with an initial delay was best fit to the time course of recovery from inactivation. The faster time constant with the much larger relative amplitude, $\tau_{\text{rec}}$, is shown for data evaluation.

**Data and statistical analysis**

Traces were displayed off-line with Clampfit software of Pclamp 10.0 (Axon Instruments). Graphics were generated using a combination of Microsoft Excel (Microsoft Corporation, Redmond, WA, USA), and Origin (version 6.1; OriginLab Inc., Northampton, MA, USA) software, statistics were performed using SigmaStat 3.1 (Statcon). All data were tested for normal distribution. For statistical evaluation t-test was used for comparing two groups. For comparing more than two groups, ANOVA on ranks (Kruskal-Wallis-Test) with Dunn’s posthoc test for not normally distributed data or one-way ANOVA (Bonferroni posthoc test) was used when data sets were normally distributed. All data are shown as means ± SEM, “n” gives the number of cells. For all statistical tests, significance with respect to control is indicated on the figures using the following symbols: *p<0.05, **p<0.01, ***p<0.001.
Results

Clinical characterization.

All four identified patients showed very similar phenotypes with neonatal-onset focal or generalized seizures remitting almost completely at 5-13 months old, followed by episodes of ataxia at least once a month starting in early childhood. All clinical data are summarized in Table 1 and more detailed case descriptions are given in Online Resource 1.

Epileptic seizures in patient #1 (Fig. 1a), carrying only the novel de novo missense mutation p.Arg1882Gly (R1882G) started at two days old with bilateral tonic-clonic seizures with reduced oxygen saturation and unresponsiveness. The seizures were initially pharmaco-resistant to phenobarbitone (PB) and valproate (VPA) but stopped by five months of age with no recurrences. Since the age of 3.7 years, episodes with slurred speech, ataxia, nausea and headache occur 1-2 times per month lasting minutes to hours. In patient #2, who carries both R1882G and also the inherited variant p.Gly1522Ala (G1522A), multifocal clonic and tonic-clonic seizures lasting 10-120 seconds occurred in the fourth week of life, and were well controlled by PB. The girl’s further course was uncomplicated until a series of generalized tonic-clonic seizures during a febrile infection at five months old. PB was changed to VPA and no further seizures occurred after the age of 5 months, also after VPA was finally discontinued at 7 years old. From 20 months of age on, episodes characterized by headache, slurred speech, impaired balance and ataxic gait occurred 1-10 times per week lasting 1-5 minutes.

Patient #3 (Fig. 1c), carrying the same de novo missense SCN2A mutation as the previously described patient #4 [3] (p.Ala263Val, A263V), presented immediately after birth with a marked muscular hypotonia and sleepiness. His development was slightly retarded. A first cluster of bilateral tonic seizures occurred at 7 days of life which was resistant to different medications (see Table 1). Oxcarbazepine (OXC) and levetiracetam (LEV) were started at 4 months of age, and the patient remained seizure-free so far from 7 months on. At 22 months, the parents reported an episode of ataxia with mild symptoms starting in the morning and inability to walk or stand in the afternoon. Further similar attacks with ataxic gait occurred since then every 10 to 14 days, lasting hours to one day. Formerly described patient #4 presented with neonatal-onset seizures with hypomotor semiology followed by tonic-clonic seizures as described previously [3]. During treatment with phenytoin (PHT), seizures became much less frequent at the age of 13 months. Since then, he has only suffered from three isolated generalized tonic-clonic seizures at the age of 3.5, 6.5 and 14.5 years. The habitual headache-ataxia episodes started at 18 months old and were pharmaco-resistant [3] until now.

Episodic ataxia in all four patients responded poorly to any of the medications tried so far (see Table 1, Online Resource 1 and discussion).
Genetics. In both patients #1 and #2 we identified the novel missense mutation c.5644C>G, p.Arg1882Gly (R1882G; GeneBank NM_021007.2, NC_000002.11). Sequencing of the parents revealed that the mutation occurred de novo in both patients. In addition, the missense variant c.4565G>C, p.Gly1522Ala (G1522A; rs147522594) was identified in patient #2. Rs147522594 was also detected in the healthy father (Fig. 1c) and occurs with an allele frequency of 0.00073% (allele count: 89/121922) within the Exome Aggregation Consortium (ExAC). Both G1522 and R1882 are completely conserved in all other 28 studied vertebrates (www.1000genomes.org). R1882G is not known to be present in unaffected individuals (www.1000genomes.org/, http://exac.broadinstitute.org/, http://www.ncbi.nlm.nih.gov/SNP/). DNA Sequencing of a cloned long range PCR fragment revealed that both variants are present on the identical allele in patient #2.

Diagnostic gene panel sequencing was performed in patient #3 [16]. The same mutation (c.788C>T, p.Ala263Val) as previously described in patient #4 was detected in SCN2A [3]. Sequencing of both parents revealed that the mutation occurred de novo

Functional studies. Electrophysiological analysis was first performed for the wild type (WT) channel in comparison with the de novo R1882G mutant, which was detected as the only SCN2A mutation in patient #1 (Fig 2). This analysis revealed a significant hyperpolarizing shift of the activation curve for mutant channels (Fig. 2d). We did not find significant differences for any other recorded gating parameter including current density (Fig. 2, Table 2, Online Resource 1 Fig. S1).

Since patient #2 carries both the de novo R1882G mutation and the inherited variant G1522A on the same allele, we additionally analyzed mutant channels carrying (i) G1522A alone, and (ii) both G1522A and R1882G (Fig. 3). Mutant G1522A alone did not reveal any significant changes compared to WT channels. Interestingly, the double mutant channel did not show changes of the activation curve (Fig. 3e), as described above for R1882G alone. In contrast, the most prominent effect for the double mutation was a 1.7-fold increase in current density compared to the other three clones, i.e. WT, G1522A and R1882G alone (Fig. 3d, Table 2). In addition, we found a significant shift of the steady-state fast inactivation curve towards more depolarized potentials only for channels carrying both variants (Fig. 3, Table 2). Consistent with the increase in current density (as a measure for the number of functional channels in the membrane), Western blot analysis of transfected tsA201 cells -to study the amount of protein expression- revealed that the total Na\textsubscript{v}1.2 protein amount was significantly increased only in channels carrying both variants in comparison to the WT (Fig. 4).

We thus found differential gain-of-function effects for Na\textsubscript{v}1.2 channels carrying either the R1882G mutation alone or both variants, R1882G and G1522A. In both cases (R1882G alone or in combination with G1522A), the changes predict an increase of membrane excitability in neurons expressing mutant Na\textsubscript{v}1.2 channels.
Discussion

We here describe patients carrying two different SCN2A mutations and comprising neonatal-onset seizures and childhood-onset episodic ataxia as the two main features. When we published the first case in 2010, it was not clear if the de novo A263V mutation in SCN2A was responsible alone for the main clinical symptoms, as migraine was a common feature in both branches of the family which could have influenced the phenotype of patient #4 [3]. Detection of a second patient (#3), with the same clinical key symptoms carrying the same mutation occurring independently de novo, now strongly suggests that this mutation is causative for both the seizures and episodic ataxia. Patients #1 and #2, carrying another de novo mutation in the same gene (in patient #2 occurring in combination with an inherited known rare polymorphism), corroborate these findings that the phenotype is caused by SCN2A gain-of-function mutations. This widens the spectrum of disorders combining epilepsy with other paroxysmal neurological symptoms such as dyskinesia or ataxia, which could be attributed to the expression of respective genes in different brain areas inducing an episodic dysfunction of neuronal networks [18-23].

The clinical characteristics of these patients in comparison to other SCN2A-associated syndromes are that seizures recurred more frequently and persisted longer than in typical BFNIS and that those were more difficult to treat [24]. In contrast to more severe epileptic encephalopathies [9-15], the seizures still remitted after 5-13 months (except for few occasional later seizures in patient #4). Since drugs have been discontinued in patient #2, seizure freedom can be attributed to spontaneous remission, whereas this remains unclear in the other cases, as treatment has been continued (patients #1 and #3) or restarted after seizure relapse during a drug-free period (patient #4). Notably, seizures in patient #3 responded well to the Na$^+$ channel blocker oxcarbazepine. Attacks of episodic ataxia with onset ranging 15 months to 3.7 years of age were the most important symptom beside the seizures. Episodic headache was an additional feature occurring in all patients, although rare and uncertain in one, and could be accompanied by back pain, discomfort and vomiting. Treatment of episodic ataxia is more difficult. Patients #1 and #4 did not respond to acetazolamide. In addition, 4-aminopyridine, which works well in the clinically rather similar episodic ataxia type 2 [25,26], did not help patient #4. The effect of Na$^+$ channel blockers, which work very well in the clinically distinct episodic ataxia type 1 with much shorter attacks triggered by sudden movements after rest [27-29], is not yet entirely clear in our patients. Theoretically, this group of antiepileptic drugs should counteract a gain-of-function of SCN2A mutations. There is increasing evidence that patients with severe early-onset epilepsies due to SCN2A mutations do respond to Na$^+$ channel blockers [30]. However, network effects are difficult to predict and could influence the response to such drugs – also in a distinct way in different brain regions – as shown recently for the hippocampus [31].

Our previous and the here presented electrophysiological data clearly indicate that different gain-of-function effects of the detected mutations in SCN2A cause the clinical phenotype. Whereas the A263V mutation causes mainly an increased
persistent Na$^+$ current [3], the \textit{de novo} mutation R1882G found in patient #1 showed a hyperpolarizing shift of the activation curve. In contrast, the combination of both variants in the same channel subunit, as detected in patient #2, leads to a prominent increase in current density, confirmed by a larger amount of produced protein, and a depolarizing shift of the steady-state inactivation curve (but no shift of the activation curve). Until now, many BFNIS-associated \textit{SCN2A} mutations – partly showing other gain-of-function mechanisms – rather exhibited a decrease in current density or cell surface expression, which however rarely reached statistical significance [3,7,17,32]. This confirms the peculiar importance of the increased current density of the combined variants found in patient #2. All observed effects predict an increased Na$^+$ inflow and a neuronal hyperexcitability, which can explain the dysfunction of cortical or cerebellar networks causing the clinical symptoms of our patients.

We have previously suggested that the age-dependent occurrence of seizures and remission in BFNIS could be due to the high Nav1.2 channel expression in axon initial segments of hippocampal and cortical pyramidal neurons early in development and their partial replacement by Nav1.6 channels with increasing maturation [7]. This mechanism could also contribute to seizure remission in the additional three cases. Although the episodic ataxia found in the studied patients might have many different causes, one hypothesis for later onset ataxia could be due to a delayed upregulation of Nav1.2 in cerebellar granule cells [7,33].

Interestingly, different substitutions of the arginine at position 1882 (R1882Q and R1882L) have been identified in two \textit{de novo} cases exhibiting epileptic encephalopathy [11] and intractable seizures, optic atrophy, severe intellectual disability, brain abnormalities and muscular hypotonia [13]. Furthermore, the A263V mutation has also been described as occurring \textit{de novo} in monozygotic twins with Ohtahara syndrome and other unique neuropathologic abnormalities [34], and a A263T mutation has been identified in a patient with a different type of early-onset epileptic encephalopathy [12]. These observations indicate that not only the mutation determines the clinical phenotype, but that other factors such as the genetic background have to play a role in genotype-phenotype relationships.

In summary, we here identified four patients with a common clinical phenotype (neonatal seizures and later onset ataxia) caused by \textit{SCN2A} mutations, which enlarges the spectrum of neurological \textit{SCN2A}-related phenotypes.
Conflicts of interest
The authors declare that they have no conflict of interest.

Ethical standards
Informed consent was obtained from the parents of all four patients. All procedures were in accordance with the Declaration of Helsinki and were approved by the local ethical review boards.
References


### Table 1 Main phenotypic characteristics of all four patients

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>c.4565G&gt;C/p.G1522A</td>
<td></td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td>male</td>
<td>female</td>
<td>male</td>
</tr>
<tr>
<td><strong>Exam at birth</strong></td>
<td>EEG at 42 conceptual weeks</td>
<td>suspected amniotic infection syndrome</td>
<td>muscular hypotonia and sleepiness</td>
</tr>
<tr>
<td></td>
<td>slightly abnormal (see text)</td>
<td></td>
<td>hypomotor activity followed by TCS on alternating sides with contralateral ictal EEG discharges</td>
</tr>
<tr>
<td><strong>Age at seizure onset</strong></td>
<td>2 d</td>
<td>24 d</td>
<td>7 d</td>
</tr>
<tr>
<td><strong>Seizure type at onset</strong></td>
<td>bilateral TCS with reduced oxygen saturation and unresponsiveness</td>
<td>multifocal CS and TCS lasting 10 s to 2 min.</td>
<td>bilateral TS</td>
</tr>
<tr>
<td><strong>Other seizure types</strong></td>
<td>TCS, tendency to clustering</td>
<td>GTCS during febrile infection</td>
<td>TS evolving into secondary GTCS</td>
</tr>
<tr>
<td><strong>Treatment (duration)</strong></td>
<td>PB (7 mo); Acetazolamide (4 mo); VPA (10 y)</td>
<td>PB (5 mo); CLZ+PHT (2 weeks); VPA (6 ½ y)</td>
<td>Vit B6 (brief); PB (brief); TPM (brief); LEV (14 mo); OXC (3 y); LTG (5 mo);</td>
</tr>
<tr>
<td><strong>Seizure outcome (age)</strong></td>
<td>seizure-free (since age 5 mo)</td>
<td>seizure-free (since age 5 mo)</td>
<td>seizure-free (since age 7 mo)</td>
</tr>
<tr>
<td><strong>Symptoms during childhood-onset episodic attacks</strong></td>
<td>paroxysmal dizziness and poor balance, slurred speech, ataxia, nausea, headache without vomiting</td>
<td>slurred speech, impaired balance, ataxic gait, headache, rarely vomiting</td>
<td>dizziness, unsteady gait, inability to walk, possibly rare painful episodes</td>
</tr>
<tr>
<td><strong>Age at onset, freq. and duration of episodes</strong></td>
<td>3.7 y; 1–2/mo; a few min to several h</td>
<td>20 mo; 1–10/w; 1-5 min (rarely repeating over 2h)</td>
<td>15 mo; 2-3/mo; 1 d</td>
</tr>
</tbody>
</table>
*: year of birth; 4-AP: 4-aminopyridine; CLZ: clonazepam; d: day(s); CS: clonic seizure; GTCS: generalized tonic-clonic seizure; h: hour(s); LTG: Lamotrigine; LEV: levetiracetam; min: minute(s); mo: month(s); OXC: oxcarbazepine; PB: phenobarbitone; PHT: Phenytion; s: second(s); TS: tonic seizure; TCS: tonic clonic seizure; TPM: topiramate; VPA: valproate; w: week(s); y: year(s)

Table 2 Current density and gating parameters for Na\textsubscript{v}1.2 WT and the mutations

<table>
<thead>
<tr>
<th></th>
<th>Steady-state activation</th>
<th>Steady-state inactivation</th>
<th>$T_{rec}$ [ms]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CD [pA/pF]</td>
<td>$V_{1/2}$ [mV]</td>
<td>$k$</td>
</tr>
<tr>
<td>SCN2A-WT</td>
<td>-450.9±54.8</td>
<td>-28.2±1.0</td>
<td>-5.7±0.2</td>
</tr>
<tr>
<td>R1882G</td>
<td>-356.7±57.2</td>
<td>-31.8±1.0</td>
<td>-5.8±0.3</td>
</tr>
<tr>
<td>G1522A</td>
<td>-448.0±78.1</td>
<td>-29.0±1.3</td>
<td>-5.3±0.3</td>
</tr>
<tr>
<td>G1522A/ R1882G</td>
<td>-757.4±136.3*</td>
<td>-28.8±1.2</td>
<td>-4.8±0.3*</td>
</tr>
</tbody>
</table>

Data are presented as means ± s.e.m. k: slope factor.

*the R1882G mutant is significantly different from the WT (p<0.05, t-test).

*the G1522A/R1882G double mutant is significantly different from the three other clones (p<0.05, one way ANOVA with Bonferroni posthoc test).

*the G1522A/R1882G double mutant is significantly different from the R1882G mutant (p<0.05, one way ANOVA with Bonferroni posthoc test).

*the G1522A/R1882G double mutant is significantly different from WT (p<0.001), from G1522A (p<0.01) and R1882G (p<0.05, one way ANOVA with Bonferroni posthoc test)
Figure legends

Fig.1 Pedigrees and SCN2A mutations in three additional cases with neonatal epilepsy and late-onset episodic ataxia. (a-c) Pedigrees of patients #1 (a), #2 (b) and #3 (c). The index patients are indicated by arrows. “+” denotes a wild type allele. A grandmother with reported Menière’s disease (a) and an aunt with reported neonatal-onset seizures (c) are marked in gray. Patients #1 and #3 carry one de novo SCN2A mutation each (a, c), whereas patient #2 carries both an inherited variant and a de novo SCN2A mutation on the same allele (b). (d) Sequence chromatograms of patient #2 and the unaffected parents showing a previously described, heterozygous c.4565G>C variant in the father and the patient, and an additional c.5644C>G mutation only in the patient. (e) Structure of the human Na\textsubscript{v}1.2 Na\textsuperscript{+} channel α subunit showing the locations of all three mutations (A263V: orange circle, G1552A: green circle, R1882G: blue circle). (f) A263V, G1522 and R1882 (red boxed) and the surrounding amino acids show high evolutionary conservation.

Fig.2 Functional studies reveal a gain-of-function for the R1882G mutation. (a-b) Families of whole-cell Na\textsuperscript{+} currents recorded from tsA-201 cells transfected with either SCN2A-WT (a) or R1882G (b) mutant channels. Sodium currents were elicited by 24 ms long step depolarizations ranging from -105 to + 97.5 mV from a holding potential of -140 mV. (c) The current density revealed no significant change in mean whole-cell peak current for R1882G mutant channels. (d) Voltage-dependence of steady-state Na\textsuperscript{+} channel activation and inactivation revealing a significant hyperpolarizing shift in the activation curve for R1882G mutant channels compared with the WT (*p<0.05, t-test). Lines represent fits of Boltzman functions. (e) The time course of recovery from fast inactivation determined at -100 mV showed no significant changes between WT and mutant channels. Lines represent fits of exponential functions yielding the time constant $T_{rec}$. All values of electrophysiological results, numbers and p-values are listed in Table 2 and are shown as mean ± SEM.

Fig.3 Functional studies reveal a different gain-of-function mechanism when both mutations G1522A/R1882G are combined. (a-c) Families of whole-cell Na\textsuperscript{+} currents recorded from tsA-201 cells transfected with either SCN2A-WT (a), G1522A mutant channels (b) or G1522A/R1882G mutant channels (c). Sodium currents were elicited as in Fig. 2. (d) The current density was significantly (1.7-fold) increased for G1522A/R1882G mutant channels (*p<0.05, one way ANOVA with Bonferroni posthoc test, Table 2). (e) Voltage-dependence of steady-state Na\textsuperscript{+} channel activation and inactivation revealing a significant depolarizing shift of the inactivation curve for G1522A/R1882G mutant channels (from WT ***p<0.001, from G1522A **p<0.01, one way ANOVA with Bonferroni posthoc test, Table 2). Lines represent fits of Boltzman functions. (f) Time course of recovery from fast inactivation determined at -100 mV, as described in Fig. 2, did not reveal significant changes between WT and mutant channels. All values of electrophysiological results, numbers and p-values are listed in Table 2 and are shown as mean ± SEM.
Fig. 4 Western Blot Analysis shows a significant increase in expression level only for the G1522A/R1882G mutation. (a) Representative experiment illustrating total Na\textsubscript{v}1.2 protein expression of tsA201 cells transfected with: only transfection reagent as Mock control, WT-Na\textsubscript{v}1.2, only G1522A, only R1882G or both G1522A/R1882G and detected with anti-pan sodium channel antibody. The immunoreactive bands of Mock-control, Na\textsubscript{v}1.2-WT or mutant proteins were normalized to the amount of the endogenous membrane-cytoskeletal protein Vinculin. (b) Quantification of six independent experiments by normalizing the signals of Na\textsubscript{v}1.2 protein bands to the corresponding Vinculin signals in total lysates demonstrated that each mutation exposed a higher level of Na\textsuperscript{+} channel expression, but only G1522A/R1882G presented a significant increase of the expression level compared to the WT (**p<0.01; N=6, one way ANOVA with Bonferroni posthoc test). All values are shown as mean ± SEM
Mother (WT/WT)
Father (G1522A/WT)
Patient (G1522A/R1882G)

<table>
<thead>
<tr>
<th>A263V</th>
<th>G1522A</th>
<th>R1882G</th>
</tr>
</thead>
<tbody>
<tr>
<td>LSVFALIGL</td>
<td>NKFQG MVFD</td>
<td>QMED RFMAS</td>
</tr>
</tbody>
</table>

Homo sapiens | Pan troglodytes | Macaca mulatta | Mus musculus | Gallus gallus | Danio rerio
---|---|---|---|---|---
LSVFALIGL | LSVFALIGL | LSVFALIGL | LSVFALIGL | LSVFALIGL | LSVFALIGL
NKFQG MVFD | NKFQG MVFD | NKFQG MVFD | NKFQG MVFD | NKFQG MVFD | NKFQG MVFD
QMEE RFMAS | QMEE RFMAS | QMEE RFMAS | QMEE RFMAS | QMED RFMAS | QMED RFMAS
Figure

(a) Western blot analysis of Na\textsubscript{V} 1.2 and Vinculin expression levels

(b) Bar graph showing normalized protein expression levels with significance **p < 0.01

- Mock
- WT
- G1522A
- R1882G
- G1522A/R1882G

250 kDa
100 kDa

Mock WT G1522A R1882G G1522A/R1882G
Click here to access/download
**Supplementary Material**
ESM_1_Resubmission.docx